Doctors fear possible contaminated counterfeit peptide batch after seventh case of acute liver damage
Medical authorities in Victoria, Australia, are investigating a cluster of acute liver toxicity cases linked to the use of counterfeit weight-loss peptides. Doctors suspect a contaminated batch of black-market retatrutide is responsible for the hospitalizations.
Why it matters
The rise of unregulated black-market pharmaceuticals poses a significant public health risk and highlights the dangers of using unapproved weight-loss products.
A seventh case of acute liver toxicity in a black-market peptide user has prompted warnings over the use of unapproved products. ( ABC News: Kylie Silvester )
There are fears a "contaminated batch" of counterfeit peptides is causing hospitalisations for acute liver toxicity.
The latest patient became seriously unwell after taking unapproved peptide labelled as retatrutide.
Doctors are testing the counterfeit peptides linked to the liver failure cases, amid warnings that unapproved products can cause serious harm.
Link copied Share Share article Another black market peptide user has suffered a severe liver injury, with doctors concerned a possible "contaminated batch" might be to blame.
The latest case means seven Victorian patients have now been hospitalised for acute liver toxicity, after using a counterfeit of the weight loss peptide retatrutide.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in